Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Research analysts at Zacks Research decreased their Q1 2025 earnings per share estimates for shares of Charles River Laboratories International in a research note issued on Wednesday, March 12th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $2.08 per share for the quarter, down from their previous estimate of $3.10. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International's Q2 2025 earnings at $2.38 EPS, Q3 2025 earnings at $2.51 EPS, Q4 2025 earnings at $2.58 EPS, FY2025 earnings at $9.55 EPS, Q1 2026 earnings at $2.46 EPS, Q2 2026 earnings at $2.66 EPS, Q3 2026 earnings at $2.71 EPS, Q4 2026 earnings at $2.78 EPS and FY2026 earnings at $10.60 EPS.
Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. UBS Group restated a "neutral" rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Morgan Stanley dropped their price target on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. Barclays lowered their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 18th. Finally, Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their price objective for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and an average price target of $191.31.
Read Our Latest Analysis on Charles River Laboratories International
Charles River Laboratories International Stock Performance
CRL traded down $8.20 during trading hours on Monday, reaching $165.68. The company's stock had a trading volume of 941,227 shares, compared to its average volume of 715,987. Charles River Laboratories International has a 52 week low of $150.79 and a 52 week high of $274.77. The company's 50-day moving average is $166.93 and its 200-day moving average is $184.11. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The firm has a market cap of $8.47 billion, a PE ratio of 1,101.40, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the prior year, the firm posted $2.46 EPS. The firm's revenue for the quarter was down 1.1% compared to the same quarter last year.
Institutional Investors Weigh In On Charles River Laboratories International
A number of hedge funds have recently added to or reduced their stakes in the business. Empirical Finance LLC increased its holdings in Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock worth $258,000 after purchasing an additional 53 shares in the last quarter. Fiduciary Financial Group LLC increased its holdings in Charles River Laboratories International by 3.9% in the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after purchasing an additional 63 shares in the last quarter. Pinnacle Bancorp Inc. increased its holdings in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares in the last quarter. M&T Bank Corp increased its holdings in Charles River Laboratories International by 3.4% in the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock worth $394,000 after purchasing an additional 66 shares in the last quarter. Finally, Cornerstone Investment Partners LLC increased its holdings in Charles River Laboratories International by 3.7% in the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock worth $358,000 after purchasing an additional 69 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.
Insider Activity at Charles River Laboratories International
In other news, COO Birgit Girshick purchased 1,514 shares of the business's stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares of the company's stock, valued at $9,064,198.54. This trade represents a 2.83 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO James C. Foster purchased 6,075 shares of the business's stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.
Charles River Laboratories International Company Profile
(
Get Free Report)
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Further Reading
Before you consider Charles River Laboratories International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.
While Charles River Laboratories International currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
